Home Antibody All anti-PARK2 antibodies
Also for PARK2 (NM_004562)
| Peptide with sequence C-DERAAEQARWEAASKE, from the internal region of the protein sequence according to NP_004553.1; NP_054642.1; NP_054643.1.|
|Test: Human. Expected from seq similarity: Human, Mouse, Rat, Dog
||ELISA: 1:128,000. WB: 0.1-0.3µg/ml.
|Supplied at 0.5 mg/ml in Tris saline, 0.02% sodium azide, pH7.3 with 0.5% bovine serum albumin.|
| Purified from goat serum by ammonium sulphate precipitation followed by antigen affinity chromatography using the immunizing peptide. Supplied at 0.5 mg/ml in Tris saline, 0.02% sodium azide, pH7.3 with 0.5% bovine serum albumin. Aliquot and store at -20°C. Minimize freezing and thawing.
|Homo sapiens parkin RBR E3 ubiquitin protein ligase (PARK2), transcript variant 1|
|AR-JP; LPRS2; PDJ; PRKN|
Entrez Gene 5071 Human
Entrez Gene 50873 Mouse
Entrez Gene 56816 Rat
Entrez Gene 612316 Dog
|The precise function of this gene is unknown; however, the encoded protein is a component of a multiprotein E3 ubiquitin ligase complex that mediates the targeting of substrate proteins for proteasomal degradation. Mutations in this gene are known to cause Parkinson disease and autosomal recessive juvenile Parkinson disease. Alternative splicing of this gene produces multiple transcript variants encoding distinct isoforms. Additional splice variants of this gene have been described but currently lack transcript support. [provided by RefSeq]. |
| Ubiquitin mediated proteolysisParkinson's disease|
* Availability is in business days
* OriGene provides validated application data and protocol, with money back guarantee.
TA303148 (0.1µg/ml) staining of Human Brain (frontal cortex) lysate (35µg protein in RIPA buffer). Primary incubation was 1 hour. Detected by chemiluminescence.